Brain derived neurotrophic factor and serotonin transporter binding as markers of clinical response to fluoxetine therapy in children with autism.

@article{Makkonen2011BrainDN,
  title={Brain derived neurotrophic factor and serotonin transporter binding as markers of clinical response to fluoxetine therapy in children with autism.},
  author={Ismo Makkonen and Raili Sylvia Riikonen and Jyrki T. Kuikka and Hannu Kokki and Joseph P. Bressler and Cathleen Marshall and Walter E. Kaufmann},
  journal={Journal of pediatric neurology : JPN},
  year={2011},
  volume={9 1},
  pages={
          1-8
        }
}
Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), has shown favorable effects in some children with autism. There are no previous studies evaluating the connection between clinical outcome and markers of clinical response to fluoxetine treatment. We examined serum brain derived neurotrophic factor (BDNF) concentrations and serotonin transporter (SERT) binding in the medial frontal cortex and midbrain, measured by single photon emission computed tomography (SPECT) scanning, in a group… CONTINUE READING
BETA